Vyalev combines foscarbidopa, a prodrug of carbidopa, and foslevodopa, a prodrug of levodopa, into a solution for continuous subcutaneous 24-hour infusion. The Food and Drug Administration (FDA) has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback